Kexing Pharmaceuticals (688136.SH): Repurchased a total of 1.308,200 shares of the company's shares
Gelonghui May 5 丨 Kexon Pharmaceuticals (688136.SH) issued an announcement that the company did not repurchase shares in April 2024. As of April 30, 2024, the company has repurchased a total of 1.3082 million shares of the company through centralized bidding transactions through the Shanghai Stock Exchange trading system, accounting for 0.66% of the company's total share capital. The highest price of the repurchase transaction was 16.77 yuan/share, the lowest price was 14.30 yuan/share, and the total amount of capital paid was RMB 199,973 million (not including transaction fees).
Conn Bay (600572.SH): Cumulative repurchase of 51.45 million shares of the company
Glonghui, May 5, 丨 Conn Bay (600572.SH) announced that as of April 30, 2024, the company had repurchased a total of 51.46.45 million shares of the company's shares through centralized bidding transactions at the Shanghai Stock Exchange, accounting for 2.00% of the company's total share capital. The highest repurchase transaction price was 5.00 yuan/share, the lowest price was 4.08 yuan/share, and the total capital commission used was 245.9663 million yuan (excluding transaction fees such as stamp duty and transaction fees).
Kexon Pharmaceuticals (688136.SH): Paclitaxel for injection (albumin binding type) has passed EU GMP certification
Kexon Pharmaceuticals (688136.SH) issued an announcement. The company recently received from the Norwegian Drug Administration according to the European Drug Administration...
There May Be Reason For Hope In Zhuhai Rundu Pharmaceutical's (SZSE:002923) Disappointing Earnings
The market was pleased with the recent earnings report from Zhuhai Rundu Pharmaceutical Co., Ltd. (SZSE:002923), despite the profit numbers being soft. We think that investors might be looking at som
SMO ClinPlusLTD's (SZSE:301257) Earnings Are Of Questionable Quality
Despite posting some strong earnings, the market for SMO ClinPlus CO.,LTD.'s (SZSE:301257) stock hasn't moved much. We did some digging, and we found some concerning factors in the details. SZSE:3
These Analysts Just Made An Incredible Downgrade To Their Shijiazhuang Yiling Pharmaceutical Co., Ltd. (SZSE:002603) EPS Forecasts
The analysts covering Shijiazhuang Yiling Pharmaceutical Co., Ltd. (SZSE:002603) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for